Actinium Pharmaceuticals, Inc. — Form 8-K
Filed October 15, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Actinium Pharmaceuticals announced the appointment of Matt David, M.D. as CFO effective October 15, 2026. Dr. David, who holds an M.D. from NYU and has 20+ years of biopharmaceutical leadership experience, joins from CorMedix Inc. where he served as EVP and Chief Business Officer. No compensation details, equity grants, or departure of prior CFO are disclosed in this filing.
Why this rating
Leadership change is material for small biotech ($43.7M cap), but appointment of qualified CFO is routine governance event. No financial or strategic impact disclosed; no departure crisis indicated.
See more from October 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.